2Seventy Bio Inc Introduction to 2seventy's Pipeline and Next-Gen Multiple Myeloma Strategy Conference Call Transcript
Good day, and thank you for standing by. Welcome to the 2seventy bio Research Deep Dive Session One Conference Call.
(Operator Instructions)
I would now like to hand the conference over to your speaker today, Nick Leschly, Chief Kairos Officer, 2seventy bio.
Thank you very much. I appreciate it. And I appreciate everyone joining us here this morning for a bit of an unusual session in the sense that typically we just jump into Q&A and do a typical investor discussion. In this case, we thought it made more sense -- as we're launching 2seventy here in the coming weeks, we thought it was good to sort of dive in, in more detail into a number of things that we're up to. So that's what this session is all about. We really appreciate all of you joining. And if you flip to the agenda slide, here on Slide 2, you can see it's a bit of an aggressive agenda, but we are trying to get through the material in sort of one run so we can focus on questions for each of you as you want to dig
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |